Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial

Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T02:14:10.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.3%
    Check dated 2025-01-19T12:13:39.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    1.0%
    Check dated 2025-01-12T07:16:49.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.3%
    Check dated 2024-12-14T12:17:15.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The website has been updated from version v2.12.2 to v2.13.2, indicating a new release with potential improvements or features.
    Difference
    0.3%
    Check dated 2024-12-07T10:26:14.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    No new additions were noted, but a significant section of content related to downloading data formats and selecting study fields has been removed.
    Difference
    13%
    Check dated 2024-11-23T04:01:42.000Z thumbnail image

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.